Argenx Se · EURONEXT:ARGX
Argenx — Q3 2026 Earnings Presentation
14 slides from Argenx's earnings presentation, Oct 22, 2026
Slide 1: 3Q 2026 Financial Results Call
Leading a new era of innovation in immunology 3Q 2026 Financial Results Call | October 22,2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Connecting science and patients to unlock infinite opportunity
Connecting science and patients to unlock infinite opportunity Science Patients 3
Slide 4: Moving Towards Reaching 50,000 Patients in 2030
Moving Towards Reaching 50,000 Patients in 2030 Up to 5 potential launches in 2027 Pipeline programs in registrational development; potential for launch, and timing of same, subject to clinical trial results and regulatory review and approval. 4 Efgartigimod Pediatric gMG IMNM Ocular MG Autoinjector
Slide 5: Empasiprubart: Entrepreneurial Science in Action
Empasiprubart: Entrepreneurial Science in Action 12k patients across key markets 1. PPTA, Takeda, CSL, argenx analysis argenx market research 60% Progression despite treatment 40% Initially misdiagnosed Targeted treatments 0 UNMET NEED Progressive and often misdiagnosed as ALS Severe disability in 2
Slide 6: FB102: Phase 3-Ready with Pipeline-in-a-Product Potential
FB102: Phase 3-Ready with Pipeline-in-a-Product Potential Phase 3 Moving to 6 Expand into alopecia areata, vitiligo and other autoimmune diseases Advancing subcutaneous option Positive Phase 2 data in celiac disease Applying the argenx playbook to FB102 First Phase 2 evidence that CD122 can prevent
Slide 7: Year-over-Year Growth of 54%: Product Net Sales of $1.7 Billion in Q3
Year-over-Year Growth of 54%* Product Net Sales of $1.7 Billion in Q3 Year over Year (YoY) growth: 3Q26 vs 3Q25 YoY Growth % * GrowthQ3 2025Q3 2026(in millions of $) 53%5079641,471US 47%216081Japan 1) 70%6494158Rest of the World 23%2911China supply 54%5941,1271,721Total 54%5921,1181,710Total ex-Chin
Slide 8: Q3 2026 Financial Summary
Q3 2026 Financial Summary *Comparative figures have been aligned with the presentation adopted in the current period, reflecting the combination of research and development expenses and loss from investment in a joint venture. † Alternative Performance Measure (APM). Refer to the APM Statement. (in
Slide 9: Patient-first Commercial Execution
Patient-first Commercial Execution VYVGART Patient Strong quarterly patient growth in MG and CIDP Seronegative driving halo effect across MG Consistent CIDP patient and prescriber adds 9
Slide 10: VYVGART Has the Broadest gMG Label
VYVGART Has the Broadest gMG Label 1. AANEM 2026 real-world IQVIA data; MSE = minimal symptom expression. Seronegative Launch Halo Effect Breadth >10% of seronegative prescribers new to VYVGART Access ~96% of covered lives secured Next Growth Drivers Potential MG 2027 launches Moving earlier in trea
Slide 11: CIDP: Steady Growth Built on Evidence and Experience
CIDP: Steady Growth Built on Evidence and Experience 1. AANEM 2026: ADHERE/ADHERE+ interim analysis, Treatment-naïve analysis, Phase 4 IVIg switch study. PHOTO: GAYLE Image to come from Cristian EVIDENCE GENERATION1 5+ yrs Most extensive dataset in CIDP ~40% Stage A responders reached INCAT 0–1 87.5
Slide 12: IMNM: First Potential Step Into Rheumatology
IMNM: First Potential Step Into Rheumatology HIGH UNMET NEED No approved therapies 20,000 patients in the US FDA Breakthrough Therapy Designation 9/10 Rheumatologists likely to prescribe VYVGART for IMNM if approved 12 For people living with myositis, the goal is straightforward: regain strength and
Slide 13: We are on a bold mission
We are on a Transforming the lives of patients with severe autoimmune disease through immunology innovation bold mission 13
Slide 14: Alternative Performance Measure Statement
Alternative Performance Measure Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using the following non-IFRS financial measures, or Alternative Performance Measures (APMs): (i) cash, cash equivalents and current financial a